ClinicalTrials.gov
ClinicalTrials.gov Menu

Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03740191
Recruitment Status : Recruiting
First Posted : November 14, 2018
Last Update Posted : November 14, 2018
Sponsor:
Information provided by (Responsible Party):
EBG MedAustron GmbH

Brief Summary:
This prospective study assess the effectiveness and safety of hypofractionated proton radiotherapy in the treatment of intermediate and low risk prostate cancer.

Condition or disease Intervention/treatment Phase
Low Risk Prostate Cancer Intermediate Risk Prostate Cancer Other: EPIC questionnaire Radiation: kV x-ray images Radiation: Conebeam CT Not Applicable

Detailed Description:
The purpose of this study is to assess the effectiveness and safety of spot-scanning based hypofractionated proton radiotherapy for the treatment of intermediate and low risk prostate cancer. The treatment effectiveness is defined as freedom from biochemical failure. Treatment safety will be documented with acute and late morbidity assessments. Dose volume relationships for late side effects in organs at risk surrounding the prostate will be calculated from the dose volume histogram parameters assessed during treatment planning. Patient assessed Quality of life data including sexual function will be collected to increase our understanding how the reduction of normal tissue irradiation with proton therapy with subsequent decrease in functional impairments will overall affect the patient's life.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 297 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: "Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer" "Hypofraktionierte Protonentherapie Mit Spot-Scanning-Technik Bei Prostatakarzinom Mit Niedrigem Oder Mittlerem Risiko"
Actual Study Start Date : July 3, 2018
Estimated Primary Completion Date : July 2027
Estimated Study Completion Date : December 2027

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Proton Therapy of Prostate Cancer

Patients with low and intermediate risk are included. The following interventions are performed:

  • 'Expanded Prostate Cancer Index Composite' (EPIC) questionnaire
  • kV x-ray images
  • Conebeam CT
Other: EPIC questionnaire
The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.

Radiation: kV x-ray images
After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.

Radiation: Conebeam CT
For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.




Primary Outcome Measures :
  1. freedom from biochemical failure [ Time Frame: 5 years ]
    Freedom from biochemical failure outcomes (FFBF) following spot-scanning based, moderately hypofractionated proton therapy will be compared with results of published studies using either similar or standard dose fractionation treatment regimen and using either photon or proton therapy. Determination of e.g., PSA, IPSS, Adverse Events


Secondary Outcome Measures :
  1. Determination of the intra-fraction target movement using planar kilovoltage (kV) x-ray Imaging 5x/week or at each day of ion therapy. [ Time Frame: daily through treatment completion (up to 4 weeks: from 1st day to last day of treatment) ]
  2. Determination of the inter-fraction target and organ at risk movement using Conebeam CT 5x/week or at each day of ion therapy. [ Time Frame: daily through treatment completion (up to 4 weeks: from 1st day to last day of treatment) ]
  3. Determination of the incidence of gastrointestinal and genitourinary toxicities acute during treatment [ Time Frame: weekly through treatment completion, Months 3(±1) ]
  4. Determination of the incidence of gastrointestinal and genitourinary toxicities late at 2 years [ Time Frame: Months 24(±2) ]
  5. Determination of the incidence of gastrointestinal and genitourinary toxicities late at 5 years [ Time Frame: Months 60(±4) ]
  6. Assessment of the quality of life and sexual function following proton therapy. [ Time Frame: Baseline, Months 3(±1), 6(±2), 12(±2), 18(±2), 24(±2), 36(±4), 48(±4), 60(±4) ]
    Change of quality of life and sexual function from Baseline following proton therapy. The Prostate cancer-specific Health-Related Quality of Life questionnaire Expanded Prostate Index Composite (EPIC-26) will be used. EPIC is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. EPIC-26 was developed as a short-form version of the full EPIC. This version contains 26 item and the same 5 domains as the full version of EPIC: Urinary Incontinence, Urinary Irritative/Obstructive, Bowel, Sexual, and Hormonal. Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better quality of life.

  7. Correlation of adverse events (toxicity), quality of life (QoL) and sexual function with dosevolume histogram parameters adjusted according to actual dose delivered. [ Time Frame: Dose volume histogram parameters: Pre-Treatment, Toxicity: Weekly during proton therapy, Months 3(±1), 6(±2), 12(±2), 18(±2), 24(±2), 36(±4), 48(±4), 60(±4), Quality of life: Pre-Treatment, Months 3(±1), 6(±2), 12(±2), 18(±2), 24(±2), 36(±4) ]
    Correlation of adverse events (toxicity) (see Determination of the incidence of gastrointestinal and genitourinary toxicities), quality of life (QoL) and sexual function (see Assessment of the quality of life and sexual function) with dosevolume histogram parameters adjusted according to actual dose delivered.

  8. Determine disease specific survival at 5 years. [ Time Frame: 5 years ]
  9. Determine overall survival at 5 years. [ Time Frame: 5 years ]
  10. Determination of the intra- and inter- mobility of prostate, seminal vesicles and rectum in order to further define and refine planning target volume parameters for future applications. [ Time Frame: daily through treatment completion (up to 4 weeks: from 1st day to last day of treatment) ]
    Determination of the intra- and inter- mobility of prostate, seminal vesicles and rectum in order to further define and refine planning target volume parameters for future applications by using data assessed by determination of the intra-fraction target movement using planar kV x-ray imaging 5x/week or at each day of ion therapy (see Determination of the intra-fraction target movement using planar kilovoltage (kV) x-ray Imaging 5x/week or at each day of ion therapy) and determination of the inter-fraction target and organ at risk movement using Conebeam CT (see Determination of the inter-fraction target and organ at risk movement using Conebeam CT 5x/week or at each day of ion therapy).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathological (histologically) proven diagnosis of prostatic adenocarcinoma
  • Clinical stage T1-T2b
  • Prostate specific antigen (PSA) ≤ 20 ng/mL
  • Gleason Score ≤ 7
  • Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
  • Clinically negative lymph nodes evaluated by imaging (pelvic +/- abdominal CT or MRI scan)
  • Any patient with lymph nodes > 1.0 cm maximum diameter requires further studies to address eligibility. Positron emission tomography (PET)-CT is recommended for lymph nodes > 1.0 cm. Positive PET-CT indicates malignant involvement. Hence, the patient will be staged as "high-risk" and therefore declared ineligible for study participation. Negative PET-CT in lymph nodes 1.0-1,5 cm indicates non-involvement and thus eligibility. Negative PET-CT in lymph nodes > 1.5 cm is equivocal and requires additional work-up, preferably by biopsy.
  • Patients must be 18 years of age or older. There is no upper age limit.
  • Patient must be able to provide study-specific informed consent prior to study entry.
  • Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) Questionnaire to assess Quality of Life.
  • Previously initiated Androgen Deprivation Therapy (ADT) is acceptable.
  • Patients with history of chronic bowel diseases may be included.
  • Patients with previous Transurethral Resection of the Prostate (TURP) performed for urinary retention may be included.

Exclusion Criteria:

  • Prior radiotherapy to the pelvic area.
  • Prior prostate cancer therapy such as: prostatectomy, cryotherapy or hyperthermia.
  • Prior systemic therapy (chemotherapy) for prostate cancer.
  • Concurrent cytotoxic chemotherapy for prostate cancer.
  • Evidence of distant metastases.
  • Regional lymph node involvement.
  • International Prostate Symptom Score (IPSS) > 20
  • Hip prosthesis
  • Second invasive malignancy (except of basal cell and squamous cell carcinoma of the skin in situ) if not controlled within last two years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03740191


Contacts
Contact: Petra Georg, Priv. Doz. Dr. +43 2622 26 100 ext 356 petra.georg@medaustron.at
Contact: Eugen B. Hug, Uni. Prof. Dr. +43 2622 26 100 ext 102 eugen.hug@medaustron.at

Locations
Austria
EBG MedAustron GmbH Recruiting
Wiener Neustadt, Niederösterreich, Austria, 2700
Contact: Petra Georg, Priv. Doz. Dr.    +43 2622 26 100 ext 356    petra.georg@medaustron.at   
Contact: Eugen B. Hug, Uni. Prof. Dr.    +43 2622 26 100 ext 102    eugen.hug@medaustron.at   
Sponsors and Collaborators
EBG MedAustron GmbH
Investigators
Principal Investigator: Petra Georg, Priv. Doz. Dr. EBG MedAustron GmbH

Responsible Party: EBG MedAustron GmbH
ClinicalTrials.gov Identifier: NCT03740191     History of Changes
Other Study ID Numbers: PRLI-MA-012016
PRLI ( Other Identifier: EBG MedAustron GmbH )
First Posted: November 14, 2018    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases